Literature DB >> 15171713

Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1).

M A Greeve1, R K Allan, J M Harvey, J M Bentel.   

Abstract

Androgens inhibit the growth of breast cancer cells in vitro and in vivo by mechanisms that remain poorly defined. In this study, treatment of asynchronously growing MCF-7 breast cancer cells with the androgen, 5alpha-dihydrotestosterone (DHT), was shown to inhibit cell proliferation and induce moderate increases in the proportion of G1 phase cells. Consistent with targeting the G1-S phase transition, DHT pretreatment of MCF-7 cultures impeded the serum-induced progression of G1-arrested cells into S phase and reduced the kinase activities of cyclin-dependent kinase (Cdk)4 and Cdk2 to less than 50% of controls within 3 days. DHT treatment was associated with greater than twofold increases in the levels of the Cdk inhibitor, p27(Kip1), while p21(Cip1/Waf1) protein levels remained unchanged. During the first 24 h of DHT treatment, levels of Cdk4-associated p21(Cip1/Waf1) and p27(Kip1) were reduced coinciding with decreased levels of Cdk4-associated cyclin D3. In contrast, DHT treatment caused increased accumulation of Cdk2-associated p21(Cip1/Waf1), with no significant alterations in levels of p27(Kip1) bound to Cdk2 complexes. These findings suggest that DHT reverses the Cdk4-mediated titration of p21(Cip1/Waf1) and p27(Kip1) away from Cdk2 complexes, and that the increased association of p21(Cip1/Waf1) with Cdk2 complexes in part mediates the androgen-induced growth inhibition of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15171713     DOI: 10.1677/jme.0.0320793

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  26 in total

1.  Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.

Authors:  Xiaoqiang Wang; Catherine Gérard; Jean-François Thériault; Donald Poirier; Charles J Doillon; Sheng-Xiang Lin
Journal:  J Mol Cell Biol       Date:  2015-05-12       Impact factor: 6.216

2.  17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.

Authors:  Juliette A Aka; Mausumi Mazumdar; Chang-Qing Chen; Donald Poirier; Sheng-Xiang Lin
Journal:  Mol Endocrinol       Date:  2010-02-19

Review 3.  Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression.

Authors:  Henriett Butz; Attila Patócs
Journal:  Cancer Metastasis Rev       Date:  2022-06-27       Impact factor: 9.264

4.  Cooperative Dynamics of AR and ER Activity in Breast Cancer.

Authors:  Nicholas C D'Amato; Michael A Gordon; Beatrice Babbs; Nicole S Spoelstra; Kiel T Carson Butterfield; Kathleen C Torkko; Vernon T Phan; Valerie N Barton; Thomas J Rogers; Carol A Sartorius; Anthony Elias; Jason Gertz; Britta M Jacobsen; Jennifer K Richer
Journal:  Mol Cancer Res       Date:  2016-08-26       Impact factor: 5.852

5.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

6.  5α-Dihydrotestosterone regulates the expression of L-type calcium channels and calcium-binding protein regucalcin in human breast cancer cells with suppression of cell growth.

Authors:  Ricardo Marques; Carina G Peres; Cátia V Vaz; Inês M Gomes; Marília I Figueira; Elisa Cairrão; Ignacio Verde; Cláudio J Maia; Sílvia Socorro
Journal:  Med Oncol       Date:  2015-08-09       Impact factor: 3.064

Review 7.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28

8.  DHEA metabolites activate estrogen receptors alpha and beta.

Authors:  Kristy K Michael Miller; Numan Al-Rayyan; Margarita M Ivanova; Kathleen A Mattingly; Sharon L Ripp; Carolyn M Klinge; Russell A Prough
Journal:  Steroids       Date:  2012-11-02       Impact factor: 2.668

9.  Androgen receptor as a targeted therapy for breast cancer.

Authors:  Joseph P Garay; Ben H Park
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

10.  Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7.

Authors:  Juliette Adjo Aka; Juliette Adjo Aka; Sheng-Xiang Lin
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.